SCHEMBL18220172

SCHEMBL18220172

COCCNC(=O)/C(C#N)=C(\C)c1ccc(-c2ccc3cc(N4CCCCC4)ccc3c2)s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.42
KMT2A Q03164 9/20 0.38
MEN1 O00255 7/20 0.38
KDM4E B2RXH2 4/20 0.38
GAA P10253 3/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ALDH1A1 P00352 6/20 0.38
MAPT P10636 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
RXFP1 Q9HBX9 1/20 0.38
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
HPGD P15428 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18220189 0.93 APP (0.43) APPKMT2AMEN1KDM4EALDH1A1
SCHEMBL24068460 0.92 APP (0.38) APPKMT2AMEN1KDM4EGAA
SCHEMBL18220177 0.92 APP (0.44) APPKMT2AMEN1KDM4EGAA
SCHEMBL23134879 0.89 APP (0.34) APPKMT2AMEN1GAAMAPT
SCHEMBL18219999 0.85 APP (0.48) APPKMT2AMEN1KDM4EGAA
SCHEMBL19293972 0.85 APP (0.39) APPALDH1A1MAPTRXFP1
SCHEMBL17120805 0.85 APP (0.34) APP
SCHEMBL18220286 0.85 APP (0.34) APPKMT2AMEN1ALDH1A1MAPT
SCHEMBL21226381 0.84 APP (0.40) APPKMT2AMEN1KDM4EGAA
SCHEMBL18220166 0.83 APP (0.42) APPKMT2AMEN1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 US disclosed
US-20170248616-A1 IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT Amydis, Inc. 2017-08-31 US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 APP 1/4885KMT2A 4649/4885MEN1 2997/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 APP 1/4885KMT2A 4649/4885MEN1 2997/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA APP 1/4885KMT2A 4621/4885MEN1 2973/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA APP 1/4885KMT2A 4621/4885MEN1 2973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.